Updating monitoring strategies and combining them with the latest technology can streamline clinical trial processes to generate higher quality data and increase patient safety, says Brett Wilson.

Updating monitoring strategies and combining them with the latest technology can streamline clinical trial processes to generate higher quality data and increase patient safety, says Brett Wilson.

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who ...

In this new publication, ACRO’s RBQM Working Group provides a real-life example of centralized monitoring implementation using a clinical trial from clinicaltrials.gov. “Centralized monitoring ...

Conduit Pharmaceuticals has signed an agreement with Sarborg to leverage advanced AI and cybernetics for the optimisation of processes related to key drug development. These include the repurposing ...

Precision for Medicine supplies clinical trial monitoring and management services to pharmaceutical and biotechnology companies, including in Australia. CROs provide services to drug sponsors and ...

“Active monitoring” is a strategy in which patients ... They conducted a multicenter, randomized clinical trial that enrolled 995 patients with grade 1 or 2, HR-positive, HER2-negative DCIS ...

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, ...

"Centralized monitoring provides a holistic view of aggregate clinical trial data and earlier identification of emergent issues, enabling organizations to make data-driven decisions more quickly ...